These findings suggest that HDAC8 inhibitors have potential clinical applications in liver cancer treatment and, when combined with immune checkpoint blockers, can enhance the post-treatment anti-tumor immune response [107] (Figure 4). This evidence concerns the gene HDAC8 and neoplasm.